Portrait of a leader in immunotherapeutics: oncolytic viruses for treatment of cancer.
When I heard about the concept of immunotherapeutics, I immediately loved it. Everything I had learned about medicine, cancer biology, genetics and oncology indicated to me that this was a potent approach, and at the time,  completely untapped. I figured that since we had been unable to cure most metastatic solid tumors, something completely different needed to be employed. Realistically, "magic bullets" are not easy to find and therefore something that can be combined with other therapies, for enhanced synergy without overlapping adverse events, would be appealing.
K. Albin Johansson Research Professor, Finnish Cancer Institute, Group leader, Cancer Gene Therapy Group, Haartman Institute, University of Helsinki, Helsinki, Finland. akseli.hemminki@helsinki.fi
Akseli
A
Hemminki
D001688:Biological Products / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D050504:Oncolytic Viruses / Q000254:growth & development*
D001688:Biological Products